Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Cancer-associated p53 missense mutants confer (GOF) and promote tumorigenesis by regulating crucial signaling pathways. However, the role of GOF mutant p53 in regulating DNA replication, a commonly altered pathway in cancer, is less explored. Here, we show that enhanced Cdc7-dependent replication initiation enables mutant p53 to confer oncogenic phenotypes. We demonstrate that mutant p53 cooperates with the oncogenic transcription factor Myb and transactivates Cdc7 in cancer cells. Moreover, mutant p53 cells exhibit enhanced levels of Dbf4, promoting the activity of Cdc7/Dbf4 complex. Chromatin enrichment of replication initiation factors and subsequent increase in origin firing confirm increased Cdc7-dependent replication initiation in mutant p53 cells. Further, knockdown of significantly abrogates mutant p53-driven cancer phenotypes and Importantly, high expression significantly correlates with p53 mutational status and predicts poor clinical outcome in lung adenocarcinoma patients. Collectively, this study highlights a novel functional interaction between mutant p53 and the DNA replication pathway in cancer cells. We propose that increased Cdc7-dependent replication initiation is a hallmark of p53 mutations.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5666604PMC
http://dx.doi.org/10.15252/embr.201643347DOI Listing

Publication Analysis

Top Keywords

mutant p53
24
replication initiation
20
cdc7-dependent replication
16
p53
10
dna replication
8
pathway cancer
8
cancer cells
8
p53 cells
8
increased cdc7-dependent
8
replication
7

Similar Publications

Ovarian and endometrial cancers frequently harbor a mutation in the tumor suppressor gene TP53, which occurs in over 90 % of ovarian cancers and in the most aggressive endometrial cancers. The normal tumor suppressive functions of p53 are disrupted, resulting in unregulated cell growth and therapeutic resistance to standard treatments including chemotherapy and PARP inhibitors. Hence, a novel therapeutic strategy is urgently needed for p53 mutant gynecologic cancers, and we propose that converting mutant p53 to a wild type conformation and restoring its tumor suppressive functions has the potential to greatly improve treatment.

View Article and Find Full Text PDF

Chemogenetic tuning reveals optimal MAPK signaling for cell-fate programming.

Cell Rep

September 2025

Department of Chemical Engineering, MIT, Cambridge, MA 02139, USA. Electronic address:

Cell states evolve through the combined activity of signaling pathways and gene networks. While transcription factors can direct cell fate, these factors rely on a receptive cell state. How signaling levels contribute to the emergence of receptive cell states remains poorly defined.

View Article and Find Full Text PDF

Prognosis of HPV-independent, p53-wild-type vulvar squamous cell carcinoma: A systematic review and meta-analysis.

Gynecol Oncol

September 2025

Pathology Unit, Department of Oncology, ASST Sette Laghi, Varese, Italy; Department of Medicine and Technological Innovation, University of Insubria, Varese, Italy. Electronic address:

Background: Vulvar squamous cell carcinoma (VSCC) is subdivided into TP53-mutant (TP53) and HPV-associated (HPV). In recent years, a third group unrelated to TP53 mutation or HPV-association (TP53/HPV) has emerged. However, its prognosis is unclear.

View Article and Find Full Text PDF

Acute myeloid leukemia (AML) is a heterogeneous disease characterized by a broad spectrum of molecular alterations that influence clinical outcomes. mutations define one of the most lethal subtypes of acute myeloid leukemia (AML), driving resistance to nearly all available treatment modalities, including venetoclax plus azacitidine (VenAza). Yet, the molecular basis of this resistance, beyond affecting transactivation of BCL-2 family genes, has remained elusive.

View Article and Find Full Text PDF

Pharmacologic interrogation of USP28 cellular function in p53 signaling.

Cell Chem Biol

September 2025

Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA. Electronic address:

Deubiquitinating enzymes (DUBs) are crucial regulators of ubiquitin signaling and protein degradation that remain incompletely understood in part due to the lack of high-quality chemical probes. To address this challenge, we developed CAS-010, a low nanomolar, ubiquitin-competitive inhibitor of USP28 that demonstrates preferential activity against USP28 over other DUBs, while also exhibiting some activity against the closely related USP25. We rationalized our SAR trends and observed selectivity using a crystal structure of USP28 in complex with an inhibitor.

View Article and Find Full Text PDF